Could this Healthcare Stock really climb 322.91% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Ad [Revolutionary Device Redefines Cancer Detection]( [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- March 05, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Ad [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [Coherus BioSciences, Inc.]( Symbol: [CHRS]( Recent Price: $2.27 Average Analyst Price Target: $9.60 (322.91%) Market Cap: $252.80M Last Year's EPS: $-0.38 Consensus EPS Forecast: $-0.21 Expected Earnings Date: Mar 06, 2024 Recent Analyst Action: Balaji Prasad, analyst at Barclays, reiterates coverage on [Coherus BioSciences, Inc. (CHRS)]( in the Healthcare sector with a Buy rating and a price target of $7 (1 month ago). [TipRanks.com]( also reports that [Coherus BioSciences, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $9.60 . The target pricing ranges from a high forecast of $9 down to a low forecast of $11. [Coherus BioSciences, Inc. (CHRS)](’s last closing price was $2.27 which would put the average price target at 322.91% upside. Here are 3rd party ratings for [CHRS](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Top 33% (82 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [ChatGPT, iOS and the Better AI Play...]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- [Victoria's Secret & Co.]( Symbol: [VSCO]( Recent Price: $26.20 Average Analyst Price Target: $28.40 (8.40%) Market Cap: $2.03B Last Year's EPS: $0.24 Consensus EPS Forecast: $-0.8 Expected Earnings Date: Mar 06, 2024 Recent Analyst Action: Dana Telsey, analyst at Telsey Advisory, reiterates coverage on [Victoria's Secret & Co. (VSCO)]( in the Consumer Cyclical sector with a Hold rating and a price target of $29 (3 days ago). [TipRanks.com]( also reports that [Victoria's Secret & Co.]( currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $28.40 . The target pricing ranges from a high forecast of $34 down to a low forecast of $25. [Victoria's Secret & Co. (VSCO)](’s last closing price was $26.20 which would put the average price target at 8.40% upside. Here are 3rd party ratings for [VSCO](: - TipRanks.com: Hold - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Bottom 22% (197 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [Is Your Money - and Privacy - at Risk?]( digital dollar could be a major threat to both your money and your personal privacy. See how it might impact your financial freedom and data security – and what you can do to protect both. Be informed, stay ahead. [Protect Your Financial Privacy Now]( --------------------------------------------------------------- [Riley Exploration Permian, Inc.]( Symbol: [REPX]( Recent Price: $23.96 Average Analyst Price Target: $49.75 (107.64%) Market Cap: $489.41M Last Year's EPS: $1.65 Consensus EPS Forecast: $1.72 Expected Earnings Date: Mar 06, 2024 Recent Analyst Action: John M., analyst at Roth MKM, reiterates coverage on [Riley Exploration Permian, Inc. (REPX)]( in the Energy sector with a Buy rating and a price target of $49.5 (3 weeks ago). [TipRanks.com]( also reports that [Riley Exploration Permian, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $49.75 . The target pricing ranges from a high forecast of $50 down to a low forecast of $49.5. [Riley Exploration Permian, Inc. (REPX)](’s last closing price was $23.96 which would put the average price target at 107.64% upside. Here are 3rd party ratings for [REPX](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 4% (241 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Baozun Inc.]( Symbol: [BZUN]( Recent Price: $2.42 Average Analyst Price Target: $4.33 (78.93%) Market Cap: $107.76M Last Year's EPS: $-0.01 Consensus EPS Forecast: $-1.46 Expected Earnings Date: Mar 06, 2024 Recent Analyst Action: Robin Leung, analyst at Daiwa, reiterates coverage on [Baozun Inc. (BZUN)]( in the Consumer Cyclical sector with a Buy rating (3 weeks ago). [TipRanks.com]( also reports that [Baozun Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $4.33 . The target pricing ranges from a high forecast of $6.9 down to a low forecast of $3.1. [Baozun Inc. (BZUN)](’s last closing price was $2.42 which would put the average price target at 78.93% upside. Here are 3rd party ratings for [BZUN](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- [comScore, Inc.]( Symbol: [SCOR]( Recent Price: $19.30 Average Analyst Price Target: $30.00 (55.44%) Market Cap: $91.77M Last Year's EPS: $-0.11 Consensus EPS Forecast: $-0.2 Expected Earnings Date: Mar 06, 2024 Recent Analyst Action: Jason Kreyer, analyst at Craig-Hallum, reiterates coverage on [comScore, Inc. (SCOR)]( in the Communication Services sector with a Buy rating (23 hours ago). [TipRanks.com]( also reports that [comScore, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $30.00 . The target pricing ranges from a high forecast of $30 down to a low forecast of $30. [comScore, Inc. (SCOR)](’s last closing price was $19.30 which would put the average price target at 55.44% upside. Here are 3rd party ratings for [SCOR](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Bottom 33% (170 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software